C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
1.435
-0.165 (-10.31%)
At close: Apr 1, 2025, 4:00 PM
1.480
+0.045 (3.13%)
After-hours: Apr 1, 2025, 7:57 PM EDT
C4 Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Cash & Equivalents | 55.5 | 126.59 | 29.75 | 76.12 | 181.73 | Upgrade
|
| Short-Term Investments | 189.41 | 127.09 | 246.4 | 233.16 | 189.96 | Upgrade
|
| Cash & Short-Term Investments | 244.9 | 253.68 | 276.15 | 309.28 | 371.69 | Upgrade
|
| Cash Growth | -3.46% | -8.14% | -10.71% | -16.79% | 310.48% | Upgrade
|
| Receivables | 3.1 | 11.8 | 1.47 | 5.72 | 4.48 | Upgrade
|
| Prepaid Expenses | 9.76 | 5.71 | 9.93 | 10.69 | 4.84 | Upgrade
|
| Total Current Assets | 257.77 | 271.19 | 287.56 | 325.69 | 381.01 | Upgrade
|
| Property, Plant & Equipment | 63.38 | 71.09 | 77.52 | 35.05 | 16.55 | Upgrade
|
| Long-Term Investments | 22.36 | 28.01 | 60.96 | 142.2 | - | Upgrade
|
| Other Long-Term Assets | 6.1 | 6.17 | 4.81 | 3.82 | 2.58 | Upgrade
|
| Total Assets | 349.6 | 376.45 | 430.84 | 506.77 | 400.14 | Upgrade
|
| Accounts Payable | 1.33 | 1.45 | 1.17 | 4.51 | 5.68 | Upgrade
|
| Accrued Expenses | 17.49 | 15.49 | 16.66 | 13.19 | 9.06 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 2.29 | - | - | Upgrade
|
| Current Portion of Leases | 5.77 | 5.22 | 4.7 | 1.33 | 1.04 | Upgrade
|
| Current Unearned Revenue | 18.71 | 15.47 | 16.62 | 31.8 | 27.6 | Upgrade
|
| Other Current Liabilities | 1.87 | 5.14 | 3.11 | 0.41 | 0.47 | Upgrade
|
| Total Current Liabilities | 45.18 | 42.77 | 44.55 | 51.25 | 43.85 | Upgrade
|
| Long-Term Debt | - | - | 9.2 | 10.77 | 10.05 | Upgrade
|
| Long-Term Leases | 59.98 | 65.76 | 70.97 | 30.78 | 11.83 | Upgrade
|
| Long-Term Unearned Revenue | 28.46 | 21.81 | 16.9 | 24.37 | 53.62 | Upgrade
|
| Total Liabilities | 133.62 | 130.34 | 141.61 | 117.16 | 119.35 | Upgrade
|
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| Additional Paid-In Capital | 849.63 | 774.62 | 689.26 | 658.09 | 464.6 | Upgrade
|
| Retained Earnings | -633.7 | -528.38 | -395.89 | -267.72 | -183.82 | Upgrade
|
| Comprehensive Income & Other | 0.05 | -0.13 | -4.14 | -0.78 | 0.01 | Upgrade
|
| Total Common Equity | 215.99 | 246.11 | 289.23 | 389.61 | 280.79 | Upgrade
|
| Shareholders' Equity | 215.99 | 246.11 | 289.23 | 389.61 | 280.79 | Upgrade
|
| Total Liabilities & Equity | 349.6 | 376.45 | 430.84 | 506.77 | 400.14 | Upgrade
|
| Total Debt | 65.76 | 70.98 | 87.15 | 42.88 | 22.92 | Upgrade
|
| Net Cash (Debt) | 201.51 | 210.71 | 249.96 | 408.6 | 348.77 | Upgrade
|
| Net Cash Growth | -4.37% | -15.70% | -38.82% | 17.16% | 354.13% | Upgrade
|
| Net Cash Per Share | 2.90 | 4.24 | 5.12 | 8.87 | 30.67 | Upgrade
|
| Filing Date Shares Outstanding | 70.99 | 68.6 | 49.05 | 48.74 | 43.12 | Upgrade
|
| Total Common Shares Outstanding | 70.63 | 60.47 | 48.97 | 48.69 | 43.06 | Upgrade
|
| Working Capital | 212.59 | 228.42 | 243.01 | 274.44 | 337.16 | Upgrade
|
| Book Value Per Share | 3.06 | 4.07 | 5.91 | 8.00 | 6.52 | Upgrade
|
| Tangible Book Value | 215.99 | 246.11 | 289.23 | 389.61 | 280.79 | Upgrade
|
| Tangible Book Value Per Share | 3.06 | 4.07 | 5.91 | 8.00 | 6.52 | Upgrade
|
| Machinery | 10.37 | 10.18 | 10.66 | 9.48 | 8.41 | Upgrade
|
| Construction In Progress | - | - | 0.18 | - | - | Upgrade
|
| Leasehold Improvements | 4.71 | 4.71 | 4.68 | 0.54 | 0.54 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.